Downregulation of Profilin-1 Expression Attenuates Cardiomyocytes Hypertrophy and Apoptosis Induced by Advanced Glycation End Products in H9c2 Cells
暂无分享,去创建一个
Dafeng Yang | Fei Li | K. Xia | Tianlun Yang | Ya Wang | Lingyan Zhu | Xu Deng | Meifang Chen | Zhifang Pei | Minna Jiang | M. Jiang
[1] Dafeng Yang,et al. Profilin-1 contributes to cardiac injury induced by advanced glycation end-products in rats , 2017, Molecular Medicine Reports.
[2] G. Fu,et al. Erratum to: The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling , 2016, Journal of Molecular Medicine.
[3] G. Fu,et al. The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling , 2016, Journal of Molecular Medicine.
[4] J. Liao,et al. Rho Kinases and Cardiac Remodeling. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[5] Dong I. Lee,et al. Profilin modulates sarcomeric organization and mediates cardiomyocyte hypertrophy , 2016, Cardiovascular research.
[6] H. Shimokawa,et al. RhoA/Rho-Kinase in the Cardiovascular System. , 2016, Circulation research.
[7] N. Kellow,et al. Effect of diet-derived advanced glycation end products on inflammation. , 2015, Nutrition reviews.
[8] Yawei Xu,et al. SIRT1 suppresses cardiomyocyte apoptosis in diabetic cardiomyopathy: An insight into endoplasmic reticulum stress response mechanism. , 2015, International journal of cardiology.
[9] S. Yamagishi,et al. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. , 2015, International journal of cardiology.
[10] Nirmal Singh,et al. Advanced Glycation End Products and Diabetic Complications , 2014, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.
[11] J. van der Velden,et al. The physiological role of cardiac cytoskeleton and its alterations in heart failure. , 2014, Biochimica et biophysica acta.
[12] E. Abel,et al. Molecular mechanisms of diabetic cardiomyopathy , 2014, Diabetologia.
[13] V. Monnier,et al. Impaired left ventricular function and myocardial blood flow reserve in patients with long-term type 1 diabetes and no significant coronary artery disease: Associations with protein glycation , 2014, Diabetes & vascular disease research.
[14] Tianlun Yang,et al. The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs) , 2013, Cardiovascular Diabetology.
[15] G. Hageman,et al. Mild Oxidative Damage in the Diabetic Rat Heart Is Attenuated by Glyoxalase-1 Overexpression , 2013, International journal of molecular sciences.
[16] Yan Wang,et al. Profilin-1 promotes the development of hypertension-induced cardiac hypertrophy , 2013, Journal of hypertension.
[17] Tzong-Ming Shieh,et al. Cell Hypertrophy and MEK/ERK Phosphorylation are Regulated by Glyceraldehyde-Derived AGEs in Cardiomyocyte H9c2 Cells , 2013, Cell Biochemistry and Biophysics.
[18] K. Macleod,et al. Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2. , 2012, American journal of physiology. Heart and circulatory physiology.
[19] M. Zembala,et al. Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. , 2012, Annals of transplantation.
[20] S. Yuda,et al. Diabetic cardiomyopathy: pathophysiology and clinical features , 2012, Heart Failure Reviews.
[21] K. Kaibuchi,et al. Rho-Kinase/ROCK: A Key Regulator of the Cytoskeleton and Cell Polarity , 2010, Cytoskeleton.
[22] R. Webb,et al. RhoA/Rho-kinase and vascular diseases: what is the link? , 2010, Cellular and Molecular Life Sciences.
[23] A. Heagerty,et al. Diabetic cardiomyopathy--a distinct disease? , 2009, Best practice & research. Clinical endocrinology & metabolism.
[24] H. Krum,et al. Letter by Connelly et al regarding article, "Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension". , 2008, Circulation.
[25] J. McNeill,et al. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. , 2007, Cardiovascular research.
[26] Shi-Yan Li,et al. Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. , 2007, Life sciences.
[27] S. Javadov,et al. Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. , 2006, Cardiovascular research.
[28] G. Cooper,et al. Cytoskeletal networks and the regulation of cardiac contractility: microtubules, hypertrophy, and cardiac dysfunction. , 2006, American journal of physiology. Heart and circulatory physiology.
[29] H. Katus,et al. The sarcomeric Z-disc: a nodal point in signalling and disease , 2006, Journal of Molecular Medicine.
[30] J. Uribarri,et al. Diet‐Derived Advanced Glycation End Products Are Major Contributors to the Body's AGE Pool and Induce Inflammation in Healthy Subjects , 2005, Annals of the New York Academy of Sciences.
[31] M. Cooper,et al. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. , 2004, American journal of hypertension.
[32] W. Witke. The role of profilin complexes in cell motility and other cellular processes. , 2004, Trends in cell biology.
[33] J. Schaper,et al. The Cytoskeleton and Related Proteins in the Human Failing Heart , 2000, Heart Failure Reviews.
[34] J. Schaper,et al. The role of the cytoskeleton in heart failure. , 2000, Cardiovascular research.
[35] J. Squire,et al. Architecture and function in the muscle sarcomere. , 1997, Current opinion in structural biology.
[36] C. Spadaccio,et al. Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. , 2015, Recent advances in cardiovascular drug discovery.
[37] T. Murohara,et al. Diabetes-related heart failure. , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[38] Sreedhar Bodiga,et al. Advanced glycation end products: role in pathology of diabetic cardiomyopathy , 2013, Heart Failure Reviews.
[39] Yan Wang,et al. Effect of ouabain on myocardial ultrastructure and cytoskeleton during the development of ventricular hypertrophy , 2011, Heart and Vessels.